Therapies for triple negative breast cancer.

ABSTRACT:

Introduction

Triple negative breast cancer (TNBC) is a heterogeneous disease associated with a high risk of recurrence, and therapeutic options are currently limited to cytotoxic therapy. Germ-line mutations may occur in up to 20% of unselected patients with TNBC, which may serve as a biomarker identifying which patients may have tumors that are particularly sensitive to platinums and/or inhibitors of poly(ADP-ribose)polymerase. A substantial proportion of patients with TNBCs not associated with germ-line BRCA mutations may have tumors that are ‘BRCA-like’, rendering those individuals potential candidates for similar strategies.

Areas covered

The purpose of this review is to highlight the current standard and experimental treatment strategies.

Expert opinion

Recent re

SUBMITTER: Andreopoulou E 

PROVIDER: S-EPMC5995333 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature